Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Quick Stats
May 14, 202660.6
AI Score
BUY0.23
Volume Ratio
Apr 30, 2026
Next Earnings
13
+ve Days (30d)
17
-ve Days (30d)
LLY Stock Summary
Last updated May 14, 2026
LLY is currently trading at $1005.68, positioned above its 200-day moving average of $920.36, indicating a long-term uptrend. The stock has a 52-week range of $623.78 to $1133.95.
Technical Analysis: The 50-day moving average stands at $939.72, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 60.015, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.056, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates LLY at 60.6/100 with a BUY recommendation.
LLY (Eli Lilly & Co.) Indicators
Last updated May 14, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 60.015 |
| CMF (20) | 0.056 |
| ROC (10) | 7.23 |
| ADX (14) | 18.564 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 17.46 |
| AROONOSC (14) | 71.429 |
| WILLAMS %R (14) | -11.982 |
| MFI (14) | 67.852 |
LLY Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
LLY Price vs Max Options Open Interest
LLY Max Change In Options Open Interest
LLY Options - Sort by Max open Interest (near term)
14th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
LLY Daily Out of Money Options - Sort by Max open Interest (near term)
14th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
LLY Daily In the Money Options - Sort by Max open Interest (near term)
14th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
LLY Most Active Options by Volume(near term)
14th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Eli Lilly & Co. is above both 50 Day and 200 Day SMA which is considered Bullish.
LLY Moving Averages Analysis
Eli Lilly & Co. has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on May 14, 2026
Eli Lilly & Co. has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on May 14, 2026
LLY (Eli Lilly & Co.) Simple Moving Averages
Moving Averages are last updated May 14, 2026
| Days | MA |
|---|---|
| 10 | 980.89 |
| 20 | 940.5 |
| 30 | 937.09 |
| 50 | 939.72 |
| 100 | 995.13 |
| 200 | 920.36 |
LLY Fundamental Analysis
| P/E (Forward) | 26.3158 |
| P/E (Trailing) | 36.1412 |
| Market Cap ($) | 905.9 billion |
| Earnings/Share ($) | 28.11 |
| Net Proft Margin (%) | 0.3499 |
| Dividend/Share ($) | 6.23 |
| EPS Estimate Current Year ($) | 36.0736 |
| EPS Estimate Next Year ($) | 44.2826 |
| WallStreet Target Price ($) | 1209.138 |
| Most Recent Quarter |
Novo Nordisk ($NVO) stock surges 7% after FDA approval for Wegovy to treat liver disease, a major milestone in the fight against the 11th leading cause of death. Investors anticipate further gains with $LLY also showing potential for growth.
Updated 2025-08-15 19:00:04